Shopping Cart
Remove All
Your shopping cart is currently empty
Tagarafdeg (CFT1946) is an orally available PROTAC degradator targeting mutant BRAF, capable of degrading BRAF V600E (Class I), G469A (Class II), G466V (type III) mutations, and the p61-BRAF V600E splice variant. It exhibits favourable selectivity within the proteome, including for wild-type BRAF and CRAF, and inhibits tumour cell proliferation.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $479 | Inquiry | Inquiry | |
| 5 mg | $1,880 | Inquiry | Inquiry | |
| 10 mg | $2,570 | Inquiry | Inquiry |
| Description | Tagarafdeg (CFT1946) is an orally available PROTAC degradator targeting mutant BRAF, capable of degrading BRAF V600E (Class I), G469A (Class II), G466V (type III) mutations, and the p61-BRAF V600E splice variant. It exhibits favourable selectivity within the proteome, including for wild-type BRAF and CRAF, and inhibits tumour cell proliferation. |
| In vitro | In A375 cells, Tagarafdeg (CFT1946) effectively degraded BRAFV600E (Emax = 26%; DC50 = 14 nM, 24 hours) and inhibited ERK phosphorylation (IC50 = 11 nM, 24 hours) and cell growth (GI50 = 94 nM, 96 hours), while having no effect on the mutant KRAS-driven cell line HCT116. [2] |
| In vivo | METHODS: Tagarafdeg (10 mg/kg, orally, twice daily) was used to treat A375 xenograft mice, and tumor growth in the mice was observed. RESULTS: Tagarafdeg resulted in deeper tumor regression. [2] |
| Synonyms | CFT-1946, CFT1946, CFT 1946 |
| Molecular Weight | 958 |
| Formula | C45H49F2N11O9S |
| Cas No. | 2882165-79-7 |
| Smiles | CN1C=2C(C(=N1)N3C(=O)NC(=O)CC3)=CC(F)=C(C2)N4CCC(CC(=O)N5CCC6(CC5)C[C@H](CO6)N7C(=O)C=8C(N=C7)=CC=C(OC9=C(C#N)C(NS(N(CC)C)(=O)=O)=CC=C9F)C8)(O)CC4 |
| Color | White |
| Appearance | Solid |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (83.51 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.